Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT”​ (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. Heat Biologics CEO Jeffrey Wolf talks about the company’s ImPACT Therapy and two clinical trials.

To learn more about Heat Biologics visit:
www.heatbio.com